PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 3,081 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 3,081 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $213,698.16. Following the completion of the sale, the vice president owned 108,231 shares of the company’s stock, valued at approximately $7,506,902.16. This trade represents a 2.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, February 17th, Mark Elliott Boulding sold 2,813 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.29, for a total value of $194,912.77.
• On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.93, for a total value of $180,330.02.
• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.56, for a total transaction of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total value of $171,196.30.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock traded up $0.06 during trading on Friday, hitting $69.96. 702,870 shares of the stock traded hands, compared to its average volume of 1,234,628. The stock has a market cap of $5.62 billion, a P/E ratio of 8.15 and a beta of 0.48. The company has a fifty day moving average price of $75.01 and a two-hundred day moving average price of $67.78. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. During the same period in the previous year, the firm posted ($0.85) EPS. The firm’s revenue for the quarter was down 22.7% on a year-over-year basis. On average, equities research analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in PTC Therapeutics by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock worth $668,691,000 after purchasing an additional 514,204 shares during the period. Wellington Management Group LLP grew its stake in shares of PTC Therapeutics by 4.8% in the third quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after buying an additional 224,481 shares in the last quarter. Janus Henderson Group PLC lifted its position in PTC Therapeutics by 28.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after acquiring an additional 1,077,776 shares in the last quarter. State Street Corp grew its position in PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after acquiring an additional 1,071,343 shares in the last quarter. Finally, Toronto Dominion Bank boosted its stake in shares of PTC Therapeutics by 27.5% in the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock valued at $314,339,000 after purchasing an additional 891,690 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Barclays upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $68.00 to $119.00 in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Finally, Bank of America cut their price target on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday. Ten analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $80.73.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product/royalty revenue beat guidance and Sephience™ (sepiapterin) showed strong early uptake (Q4 revenue $92M; 2025 Sephience revenue $111M). Company ended 2025 with $1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America cut its price target from $97 to $93 but kept a “buy” rating, implying continued analyst conviction and a material upside from current levels. That endorsement can limit downside and attract buyers. Benzinga
• Neutral Sentiment: Earnings-call coverage and analyst note summaries are available that walk through quarter specifics and management commentary — useful for parsing whether revenue mix or one-offs drove the headline miss. Earnings Call Highlights
• Negative Sentiment: PTC reported Q4 EPS of ($1.67) vs. consensus ($0.21) and Q4 revenue of $164.7M vs. $281.5M expected — a sizeable miss that directly pressured the stock. Revenue was down ~22.7% year‑over‑year. Zacks: Q4 loss, revenue miss
• Negative Sentiment: Management set FY-2026 revenue guidance of $700M–$800M vs. street consensus near $974M — a notable downward gap that reduces near-term upside and raises investor concern about product rollouts/volume. PR Newswire: Guidance
• Negative Sentiment: Regulatory headwinds: coverage flagged new questions after PTC withdrew a Translarna NDA, adding uncertainty to that program’s prospects and potential future revenue. Yahoo: Translarna questions
• Negative Sentiment: Insider selling: VP Mark Boulding sold ~5,894 shares across Feb. 17–18, a small but visible reduction in holdings that can be perceived negatively by some investors. SEC Form 4

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.